Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 9;6:91. doi: 10.1038/s41698-022-00334-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a In the Foundation Medicine (FM) dataset of tissue or hematologic samples from 426,706 adult patients with cancer, KRAS was the most frequently altered oncogene with alterations in 23% of samples. A longtail of other top frequently altered oncogenes is shown; bar colors indicate alteration classes, SV: short variant mutation (e.g., substitutions, indels), CNA: copy number alteration, RE: rearrangement. b Prevalence in the FM dataset (left) and incidence estimates in the United States (right) of KRAS alterations in common adult tumor types (Supplemental Table 1). KRAS alterations are most prevalent in PDAC, appendix adenocarcinoma, small bowel and CRC tumor types. The highest incidence of KRAS alterations is estimated in CRC, non-Sq NSCLC and PDAC. c, d Number of cases in the FM database with KRAS mutations among (c) the 8 top indications with highest incidence of KRAS alterations and carcinoma of unknown primary (CUP) and d the 5 most common KRAS mutant isoforms.